Ingestion of the mushroom containing Amanita phalloides can induce fulminant liver failure and death. There are no specific antidotes. Blood purifications, such as molecular adsorbent recirculating system (MARS) and therapeutic plasma exchange (TPE), are potential therapies. However, the extent to which these technologies avert the deleterious effects of amatoxins remains controversial; the optimal intensity, duration, and initiation criteria have not been determined yet. This study aimed to retrospectively observe the effects of MARS and TPE on nine patients with A. phalloidesinduced fulminant liver failure. The survival rate for the nine patients was 66.7%. Both TPE and MARS might remove toxins and improve liver functions. However, a single session of TPE produced immediately greater improvements in alanine aminotransferase (−60% vs. −16.3%), aspartate aminotransferase (−47.6% vs. −15.4%), and total bilirubin (−37.3% vs. −17.1%) (compared with the values of pretreatment, all p < 0.05) than MARS compared with MARS. Early intervention may be more effective than delayed therapy. Additionally, the presence of severe liver failure and renal failure indicated worse outcome. Although these findings are promising, additional case-controlled, randomized studies are required to confirm our results. ASAIO Journal 2014; 60:407-412.
Intoxication accidents because of eating wild mushrooms happen every year in many different regions of the world. 1, 2 The clinical manifestations of mushroom poisoning vary based upon the species of mushroom, with the most severe cases, and approximately 90% of fatalities, resulting from amatoxin-containing mushrooms such as Amanita phalloides. [3] [4] [5] [6] [7] The lethal dose of amanitin or α-amatoxin can be as low as 0.1 mg/kg in humans. 8 Ingestion of even a single full-grown A. phalloides mushroom can lead to fulminant liver failure (FLF), with a mortality of 80% if liver transplantation is not possible. 9 Fulminant liver failure is defined as sudden and severe liver dysfunction associated with jaundice and altered mental status ( encephalopathy) in the absence of preexisting liver disease. 10 The primary treatment strategies are supportive measures including gastric lavage, oral activated charcoal, fluid resuscitation, and targeted organ protections. Although there are no specific antidotes for amatoxin poisoning, in recent years, extracorporeal blood purification technologies such as molecular adsorbent recirculating system (MARS), hemoperfusion, and therapeutic plasma exchange (TPE) have been used in clinical therapy. 11 There is some evidence to show that MARS or TPE can remove toxins, bilirubin, bile acids, inflammatory mediators, and improve survival after hepatic encephalopathy. [12] [13] [14] However, large-scale clinical trials have not been performed, and the extent to which these technologies avert the deleterious effects of amatoxins remains controversial. 9 This aim of this retrospective study is to observe effects of MARS or TPE on mushroom poisoning patients with severe liver failure.
Methods

Patients
We retrospectively studied patients with A. phalloides poisoning in our hospital treated with MARS or TPE between August 2011 and September 2013. Patients ages less than 16 years or more than 65 years old or died within 24 hours after admission were excluded, and the remaining nine patients were included. All nine subjects had no significant medical histories and had ingested multiple wild, white-colored mushrooms. The diagnosis of A. phalloides intoxication was established based upon the presence of classic amatoxin clinical manifestations and patient descriptions of the suspected mushroom. Permission for chart review was obtained from the ethical committee.
Routine Therapies
All patients received standard initial treatments including gastric lavage, naso-duodenal tube with continual aspiration, multiple doses of activated charcoal, penicillin G, and vitamin K. Any patients who developed hypovolemia, hypoglycemia, electrolyte imbalances, metabolic acidosis, or coagulation disorders were treated with the appropriate supportive therapies.
Extracorporeal Blood Purification Management
In addition to these basic treatments, all patients received extracorporeal blood purification in the form of MARS or TPE. The criteria for extracorporeal purification to treat mushroom poisoning are based upon 1) history of ingesting a white mushroom, 2) the typical symptoms (vomiting, epigastric abdominal pain, diarrhea) at least 6 hours after mushroom ingestion, and 3) the presence of liver dysfunction (elevation of aminotransferases or bilirubin). The decision to initiate MARS or TPE was based primarily on the patients' conditions including coagulation dysfunction, electrolyte imbalance, azotemia, or acid-base imbalance. Therapeutic plasma exchange was used as the initial treatment for all patients with an internal normalized ratio (INR) >5, unless there were insufficient amounts of plasma for the patient's blood type, and then MARS was started. Each MARS/TPE session was planned one time daily until the native liver showed signs of recovery.
A double-lumen tube was inserted into the femoral vein or the jugular vein to establish vascular access for MARS/ TPE; unfractionated heparin was used as the anticoagulation drug. Molecular adsorbent recirculating system was performed using the Teraklin machine (Teraklin, Rostock, Germany). Each MARS treatment lasted 6 hours. The blood flow rate was set to 150 ml/min, the albumin flow rate was set to 150 ml/min, and the dialysis flow rate was set to 1,000 ml/hr. Therapeutic plasma exchange was performed with the Fresenius Plasmaflu P2S machine (Fresenius Medical Care GmbH, Bad Homburg, Germany). Patients received calcium gluconate and promethazine before the treatment to help prevent allergic reactions. Each TPE treatment lasted for 2.5 hours and exchanged a total of 2,500 ml of fresh plasma. The blood flow rate was set to 150 ml/min, and the plasma flow rate was set to 1,000 ml/hr.
Measurements and Monitoring
Vital signs were monitored during treatment in the intensive care unit (ICU). Laboratory parameters including serum electrolytes, glucose, globulin, albumin, prealbumin, blood urea nitrogen, creatinine, aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, total cholesterol, lactate dehydrogenase (LDH), creatine kinase (CK), α-hydroxybuterate dehydrogenase (HBDH), prothrombin time (PT), activated partial thromboplastin time, INR, fibrinogen, and complete blood count were examined daily. Additionally, the model for end-stage liver disease score was calculated to assess the severity of liver injury in the ICU. Hepatic encephalopathy, a spectrum of neuropsychiatric abnormalities as a result of liver failure, was graded on a scale of 1-4 with the West Haven criteria, including the level of impairment of autonomy, changes in consciousness, intellectual function, behavior, and the dependence on therapy. 15
Statistical Analysis
Descriptive data are expressed as median (range). Mann-Whitney U test was used to compare the differences. Categorical variables were expressed as proportions and compared using the χ 2 test. Statistical analysis was performed using SPSS 11.0 (SPSS Inc, Chicago, IL). A two-sided p < 0.05 was considered statistically significant.
Results
Overall Demographic Clinical Data
All nine patients developed acute gastroenteritis 10-12 hours after the ingestion. After 2-3 days, all patients presented with fatigue, anorexia, dull pain on the liver, jaundice, and abnormal laboratory indexes (elevated in the liver enzymes, bilirubin, LDH, CK, and HBDH and decreased in fibrinogen, prothrombin activity, and total cholesterol). Demographic and clinical data of all patients are outlined in Table 1 . Six patients developed hepatic encephalopathy within 3-5 days of ingesting; five of these patients deteriorated rapidly. Disseminated intravascular coagulation presented in three patients, and three patients developed acute renal failure. Additionally, thrombocytopenia was present in seven patients, hypoglycemia was present in three patients, and one patient developed severe gastrointestinal bleeding. The most severe laboratory values for each patient are shown in Table 2 .
The Effects of Extracorporeal Blood Purifications
Six of the nine patients (66.7%) in this study survived amatoxin poisoning. All five patients (case 3, 6-9) who received both MARS and TPE survived; case 1, 5 who received only MARS and case 2, 4 who received only TPE died. Each Table 3) . ALT values decreased from pre-MARS levels by 16.3%, AST decreased by 15.4%, and total bilirubin (TBIL) decreased by 17.1% (p < 0.05). In addition, MARS therapy was able to decrease the heart rate (HR) by 10.2% (p < 0.05). Molecular adsorbent recirculating system had no significant influences on PT, fibrinogen, white blood cell counts (WBC), mean arterial pressure (MAP), albumin, prealbumin, or hemoglobin (Hb) (p > 0.05); however, MARS did induce a slight decrease in platelet levels (4.0%, p < 0.05). Figure 1 showed the changes of ALT, AST, TBIL, and creatinine with time for survivors and nonsurvivors. The liver injuries were much more severe in nonsurvivors and continued to worsen (measured by TBIL) even after blood purifications.
Clinical Parameters to Predict Outcomes
Complications From Blood Purification
One patient suffered a slight allergic reaction during TPE therapy. Additionally, TPE therapy resulted in decreased Hb values, albumin values, and platelet counts, but they remained within acceptable physiologic ranges (Tables 2 and 3) . Molecular adsorbent recirculating system therapy also caused a slight drop in platelet levels. No other serious adverse effects were observed after blood purification treatments.
Discussion
In our study, either MARS or TPE could diminish liver injuries induced by amatoxin-containing mushroom intoxication. Therapeutic plasma exchange therapy immediately resulted in a greater improvement in liver function as compared with MARS therapy. Early use of MARS/TPE may be able to improve the outcome. There is a trend that combined TPE and MARS therapy is more effective at ameliorating amatoxin poisoning than either single therapy. This study also showed that severe liver injury combined with severe renal injury can predict mortality from amatoxin poisoning.
The liver is recognized as the target organ for A. phalloides toxins. The overall severity of the intoxication depends on the amount of toxin ingested and the time elapsed between ingestion and initiation of treatment. In this study, liver injury began approximately 24 hours after ingestion and progressed into FLF approximately 72 hours after consumption.
Treatment of poisoning patients requires the rapid and effective elimination of the toxin and its potentially toxic metabolites. Early hemoperfusion (<24 hours after exposure) over a charcoal filter is effective in averting the deleterious effects of amatoxins. 16 Because of the rapid time course of absorption and excretion of amatoxins, hemodialysis will have a limited effect, even if applied within 24 hours of consumption. 17, 18 Molecular adsorbent recirculating system is capable of transferring protein-bound and water-soluble toxic metabolites from the blood stream into a dialysate compartment via a special membrane, 14 effectively functioning as an artificial liver for acute liver failure.
There are several case reports using MARS in the treatment of FLF secondary to mushroom poisoning in both children and adults, and for the vast majority of these patients, MARS successfully improved symptoms and biological parameters following liver damage. 19, 20 Additionally, all mushroom-poisoned patients in the MARS group of the Helsinki Study survived despite late treatment and the presence of severe liver failure. 21 Therefore, the beneficial effect of MARS was mainly related to the artificial restoration of liver function.
TPE, another traditional extracorporeal purification method, is more widely available, 22 especially for the removal of toxic substances. 13 At present, plasmapheresis is used successfully in the treatment of phalloids mushroom intoxications. 12, 22 Our report showed that TPE produced greater liver function improvements than MARS. Patients had an immediately significant improvement of PT after TPE sessions compared with MARS. The possible explanation is that TPE works through direct plasma exchange and removes the toxins immediately. Coagulation factors are also replenished during TPE, which helps to improve the coagulation functions.
Whether or not TPE is superior to other purification methods remains unknown, as the current literatures lack any such comparisons. In our study, each MARS treatment lasted 6 hours; the albumin flow rate was set to 150 ml/min. Based on the published reports, most studies set the albumin flow rate at 150-200 ml/min and last 6-8 hours in MARS. In Kantola's report, ten patients were treated with MARS within 2 days of accidental A. phalloides mushroom poisoning, with each session of MARS lasting for 15.4 hours. 23 Nine patients experienced liver recovery, and one patient was successfully bridged to liver transplantation. Whether or not increasing running time and albumin flow rate of MARS circuit have better effects remains unknown. In fact the optimal intensity, duration, and initiation criteria of MARS therapy have not been determined yet.
An interesting discovery is that all five patients who received both MARS and TPE survived; however, the power is too small to draw a firm conclusion. Based on past experiences, case 7 progressed too far for treatment; however, he received both TPE and MARS therapy on the first day of hospitalization and ultimately experienced native liver recovery. Most of our patients received both MARS and TPE on different days, if we run MARS and TPE at the same time, or at least on the same day, they may be more effective. Therapeutic plasma exchange may improve coagulation function and it appears to remove toxins. Molecular adsorbent recirculating system can remove both water-soluble and albumin bound toxins, making it a more effective to use a combination of MARS and TPE. Despite these observations, more robust studies are needed to solidify this finding.
It is generally accepted that extracorporeal decontamination treatment is more useful if started very early. From our data (Figure 1) , the worst values of liver dysfunction parameters occurred from the fourth to sixth day. The first seven patients were transferred to the ICU on the fifth or the sixth day after ingestion, three of whom died despite blood purification. It appeared as though their diseases had progressed too far for additional blood purification. As a result, the nonsurvivors had no chance to receive additional TPE/MARS sessions. The last two patients (Figure 1 , early treatment patients) received MARS and TPE on the third day after ingestion and both survived. These two patients avoided persistently worse liver injury afterwards. Taru Kantola recommended initiating MARS within 3 days after ingestion because encephalopathy or other serious complications had not developed yet in most patients. 23 Therefore, MARS/TPE treatment should be initiated as early as soon as A. phalloides ingestion has been confirmed.
There were significant differences among AST, ALT, TBIL, and creatinine, in survivors and nonsurvivors. A persistent increase in TBIL even after purifications indicates refractory liver failure, and a persistent of high level of creatinine suggests severe kidney injury (Figure 1) . All of these predicted a worse outcome. Our three patients with both FLF and ARF had 100% mortality, even after MARS therapy or TPE and hemofiltration, which were similar to the other report.
There are several limitations with this study. This was not a randomized clinical trial, and the small sample size limits the power of our findings. The choices for MARS or TPE were mainly based on the patients' conditions. The orders for the combined MARS and TPE therapies were mixed. All these affected the power of the results. The cytokines and other biomarkers, which are very important to confirm the efficacy of purifications, were not measured in this study although other reports showed supportive results. 14, 24 However, this observational report truly provides the preliminary data for further clinical trials.
Conclusions
Both MARS and TPE demonstrated the ability to remove toxins and improve liver functions as measured by the laboratory parameters, but TPE has better efficacy. Our data also showed that these therapies are more efficacious when provided early. Additionally, severe liver injury combined with kidney injury represented negative prognostic markers. Although these findings are promising, additional case-controlled, randomized studies are required to confirm our results.
